Exciting Presentations from iBio Inc.
iBio, Inc. (NASDAQ: IBIO), a pioneering biotechnology company, is gearing up to present breakthrough research on its Activin E antibody. This development showcases its commitment to addressing critical health challenges like obesity. Recently, Cory Schwartz, Ph.D., the Director of Research and Early Development at iBio, announced his upcoming oral presentation at ObesityWeek 2025, scheduled for November 4-7. This event will take place in Atlanta, focusing on innovative strategies to combat obesity.
Innovative Data from Research
The highlight of Schwartz's presentation will be data from their extensive non-human primate study of IBIO-610, an Activin E antagonist antibody. This data is pivotal as it underscores the potential of this antibody to offer a unique approach to treating obesity. As Dr. Brenner, iBio's CEO and Chief Scientific Officer, stated, the findings suggest that inhibiting Activin E signaling may facilitate fat-selective weight loss. It may also support long-term weight maintenance and enhance the effectiveness of GLP-1 therapies, ultimately aiming to transform treatment paradigms for cardiometabolic disorders.
Details of the ObesityWeek Presentation
Presentation Title: Discovery and Testing of a First-in-Class Activin E Antagonist Antibody for the Treatment of Obesity
Date: November 4, 2025
Time: 2:00 p.m. – 2:15 p.m. EST
Location: A411-A412
Poster Presentation
In addition to the oral presentation, Dr. Schwartz will also showcase a poster titled "Preclinical Evaluation of a Long-Acting Anti-Myostatin Therapy for Obesity" on November 5 at 2:30 p.m. EST, further expanding on innovative approaches in obesity treatment.
PEGS Europe Presentation Details
Martin Brenner will also be presenting at PEGS Europe 2025 from November 11-13 in Lisbon. His presentation focuses on the efficacy of IBIO-610 in inducing fat-selective weight-loss in diet-induced obese mice.
Presentation Details
Title: A First-in-Class Anti-Activin E Antibody Induces Fat-Selective Weight-Loss in Diet-Induced Obese Mice
Date: November 12, 2025
Time: 11:45 a.m. – 12:15 p.m. WET
Location: Podium Presentation
About iBio Inc.
iBio (NASDAQ: IBIO) is an innovative biotechnology firm leveraging artificial intelligence and computational biology to create next-generation biopharmaceuticals targeting various challenging diseases including obesity and cancer. Their proprietary 3D modeling enhances drug discovery processes, leading to significant advancements in antibody therapies aimed at fulfilling unmet medical requirements. iBio seeks to revolutionize the drug discovery timeline while promoting precision medicine.
Corporate Contact Information
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Frequently Asked Questions
What is the focus of iBio's upcoming presentations?
iBio will be presenting its research on the Activin E antibody, highlighting its implications for obesity treatment.
Where will these presentations be held?
The presentations are scheduled for ObesityWeek 2025 in Atlanta and PEGS Europe 2025 in Lisbon.
Who will present on behalf of iBio?
Cory Schwartz, Ph.D. will present at ObesityWeek, while Martin Brenner will present at PEGS Europe.
What is IBIO-610?
IBIO-610 is an Activin E antagonist antibody being studied for its potential to promote fat-selective weight loss.
How does iBio aim to enhance treatment for obesity?
iBio focuses on innovative approaches through advanced antibody therapies that target metabolic pathways involved in obesity.